CrossRef Circulating Estradiol as an Independent Risk Factor for Metabolic DysfunctionAssociated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort Hyo Jung Cho, Seong Hee Kang, Hye Yeon Chon, SungA Bae, Eunju Kim, Seong Kyun Na, Su Jin Kim, Dooyeon Kim, Hye Ri Ahn, Huigyeong Kim, Jae Youn Cheong, Soon Koo Baik, Young Kul Jung, Soon Sun Kim, Hyung Joon Yim Journal of Korean Medical Science .2026;[Epub] CrossRef LY6D promotes hepatic steatosis via the GRB2AMPKSREBP1 signaling axis Qiurong Zhao, Linxin Chen, Sha Xie, Juanjuan Meng, Wei Cui, Yao Wu, Ting Zeng, Huaming Mou, Xiaohe Luo International Journal of Obesity .2026
Any platform prescribing GLP-1s without capturing BMI, comorbidity history, contraindications (personal or family history of medullary thyroid carcinoma, pancreatitis, MEN2), and current medications is not meeting that guideline standard
Switching was defined as a patient with an active supply of a different GLP-1 RA in two sequential months
If you're deciding between GHK-Cu topical vs injection methods to support your cosmetic goals, topical serums may provide a more effective option to treat specific areas on the skin and scalp
The tirzepatide dose of 10 mg was next (mean difference of 1.86%), followed by semaglutide 2 mg (mean difference of 1.62%)